Edgewise Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Edgewise Therapeutics, Inc. (Nasdaq: EWTX) is a clinical-stage biopharmaceutical company historically focused on developing orally administered precision small-molecule therapies for severe muscle disorders, including muscular dystrophies and serious cardiac conditions. The company's proprietary drug discovery platform targets key muscle proteins and modulators to address underlying disease mechanics. In a transformative strategic shift announced on June 1, 2026, Edgewise entered into a definitive agreement to sell its muscular dystrophy business, including its lead clinical asset sevasemten (EDG-5506), to Servier for $1.55 billion in upfront cash and up to $1.1 billion in future milestones. Following the close of this transaction (expected in Q3 2026), Edgewise will pivot exclusively to becoming a cardiovascular-focused company. Its remaining pipeline is centered on EDG-7500, a novel cardiac sarcomere modulator in Phase 2 development for hypertrophic cardiomyopathy (HCM), and EDG-15400, which is being prepared for Phase 2 trials in heart failure with preserved ejection fraction (HFpEF).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Refocusing the entire company strategy to become a dedicated cardiovascular-focused entity following the divestiture of the neuromuscular business. The pipeline will center on EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF, and EDG-003 for an undisclosed target.
Expected impact: Establishes a well-capitalized, pure-play cardiovascular company, removing the financing risks typically associated with late-stage clinical transitions.
Advancing EDG-7500, a novel cardiac sarcomere modulator designed to address hypercontractility in hypertrophic cardiomyopathy (HCM), through Phase 2 (CIRRUS-HCM) and preparing for Phase 3 development.
Expected impact: Addresses a large patient population of over 750,000 in the US with a potentially differentiated therapeutic profile.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Monetizes the late-stage neuromuscular asset sevasemten and the muscular dystrophy business, transferring global development and commercialization responsibilities to Servier while retaining significant financial upside through milestones.
Terms: $1.55 billion in upfront cash consideration at closing, with eligibility for up to $1.1 billion in additional regulatory and commercial milestones (including up to $200 million on US approval in Becker muscular dystrophy, $600 million for Duchenne muscular dystrophy expansion, and $300 million in sales-based milestones).